Management of Heart Failure in the Hospital: A Clinical Approach
Keywords:
heart failure, heart failure management, hospitalization, multidisciplinary approachAbstract
Despite tremendous breakthroughs in drug-based and device-based therapy, heart failure continues to be a serious and growing public health issue linked with substantial disability, frequent hospitalization, and large economic expenditures. Complex therapeutic options in a population with a high frequency of comorbidity and overall frailty hinder clinical care. In recent years, significant progress has been made in the care of heart failure (HF). In this study, the most recent available evidence, the indications provided by worldwide guidelines, and expert opinion on the optimal treatment for individuals with HF will be discussed. This review, according to the authors, bridges the gap between guidelines and clinical practice and presents recommendations to improve HF management.
References
Lan T, Liao YH, Zhang J, et al. Mortality and readmission rates after heart failure: A systematic review and meta-analysis. Ther Clin Risk Manag. 2021;17:1307-1320. doi:10.2147/TCRM.S340587
Riccardi M, Sammartino AM, Piepoli M, et al. Heart failure: an update from the last years and a look at the near future. ESC Heart Fail. 2022;9(6):3667-3693. doi:10.1002/ehf2.14257
Tomasoni D, Adamo M, Anker MS, von Haehling S, Coats AJS, Metra M. Heart failure in the last year: progress and perspective. ESC Heart Fail. 2020;7(6):3505-3530. doi:10.1002/ehf2.13124
Sabouret P, Attias D, Beauvais C, et al. Diagnosis and management of heart failure from hospital admission to discharge: A practical expert guidance. Ann Cardiol Angeiol (Paris). 2022;71(1):41-52. doi:10.1016/J.ANCARD.2021.05.004
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-2200m. doi:10.1093/eurheartj/ehw128
Bozkurt B, Coats AJ, Tsutsui H, et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. 2021;27(4):387-413. doi:10.1016/J.CARDFAIL.2021.01.022
Riley JP, Masters J. Practical multidisciplinary approaches to heart failure management for improved patient outcome. European Heart Journal Supplements. 2016;18(suppl G):G43-G52. doi:10.1093/eurheartj/suw046
Sabatier R, Legallois D, Jodar M, et al. Impact of patient engagement in a French telemonitoring programme for heart failure on hospitalization and mortality. ESC Heart Fail. 2022;9(5):2886-2898. doi:10.1002/ehf2.13978
Savarese G, Lund LH, Dahlström U, Strömberg A. Nurse‐Led Heart Failure Clinics Are Associated With Reduced Mortality but Not Heart Failure Hospitalization. J Am Heart Assoc. 2019;8(10). doi:10.1161/JAHA.118.011737
Anderson SL, Marrs JC. A Review of the Role of the Pharmacist in Heart Failure Transition of Care. Adv Ther. 2018;35(3):311-323. doi:10.1007/s12325-018-0671-7
MacInnes J, Williams L. A review of integrated heart failure care. Prim Health Care Res Dev. 2019;20:e57. doi:10.1017/S1463423618000312
Okumura N, Jhund PS, Gong J, et al. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. Circ Heart Fail. 2016;9(9). doi:10.1161/CIRCHEARTFAILURE.116.003212
Niemiec R, Morawska I, Stec M, et al. ARNI in HFrEF—One-Centre Experience in the Era before the 2021 ESC HF Recommendations. Int J Environ Res Public Health. 2022;19(4):2089. doi:10.3390/ijerph19042089
Kapelios CJ, Lainscak M, Savarese G, et al. Sacubitril/valsartan eligibility and outcomes in the ESC‐EORP‐HFA Heart Failure Long‐Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM‐HF trial, ESC guidelines, and real world. Eur J Heart Fail. 2019;21(11):1383-1397. doi:10.1002/ejhf.1532
McMurray JJ V, Solomon SD, Docherty KF, Jhund PS. The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. Eur Heart J. 2021;42(13):1199-1202. doi:10.1093/eurheartj/ehz916
Anker SD, Butler J, Filippatos G, et al. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. Circulation. 2021;143(4):337-349. doi:10.1161/CIRCULATIONAHA.120.051824
Lopaschuk GD, Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors. JACC Basic Transl Sci. 2020;5(6):632-644. doi:10.1016/j.jacbts.2020.02.004
Butler J, Anker SD, Lund LH, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J. 2022;43(41):4362-4373. doi:10.1093/eurheartj/ehac401
Lombardi CM, Cimino G, Pagnesi M, et al. Vericiguat for Heart Failure with Reduced Ejection Fraction. Curr Cardiol Rep. 2021;23(10):144. doi:10.1007/s11886-021-01580-6
Metra M, Pagnesi M, Claggett BL, et al. Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. Eur Heart J. 2022;43(48):5006-5016. doi:10.1093/eurheartj/ehac293
Lewis GD, Voors AA, Cohen-Solal A, et al. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction. JAMA. 2022;328(3):259. doi:10.1001/jama.2022.11016
Damy T, Garcia‐Pavia P, Hanna M, et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial ( ATTR‐ACT ) and long‐term extension study. Eur J Heart Fail. 2021;23(2):277-285. doi:10.1002/ejhf.2027
Mullens W, Auricchio A, Martens P, et al. Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. Eur J Heart Fail. 2020;22(12):2349-2369. doi:10.1002/ejhf.2046
Sharma A, Wu J, Xu H, et al. Comparative Effectiveness of Primary Prevention Implantable Cardioverter‐Defibrillators in Older Heart Failure Patients With Diabetes Mellitus. J Am Heart Assoc. 2020;9(12). doi:10.1161/JAHA.119.012405
Giallauria F, Cuomo G, Parlato A, Raval NY, Kuschyk J, Stewart Coats AJ. A comprehensive individual patient data meta‐analysis of the effects of cardiac contractility modulation on functional capacity and heart failure‐related quality of life. ESC Heart Fail. 2020;7(5):2922-2932. doi:10.1002/ehf2.12902
Ningyan W, Keong YK. Percutaneous Edge-to-Edge Mitral Valve Repair for Functional Mitral Regurgitation. International Journal of Heart Failure. 2022;4(2):55. doi:10.36628/ijhf.2021.0041
Orban M, Besler C, Braun D, et al. Six‐month outcome after transcatheter edge‐to‐edge repair of severe tricuspid regurgitation in patients with heart failure. Eur J Heart Fail. 2018;20(6):1055-1062. doi:10.1002/ejhf.1147
Schlotter F, Miura M, Kresoja KP, et al. Outcomes of transcatheter tricuspid valve intervention by right ventricular function: a multicentre propensity-matched analysis. EuroIntervention. 2021;17(4):e343-e352. doi:10.4244/EIJ-D-21-00191
Marrouche NF, Brachmann J, Andresen D, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. New England Journal of Medicine. 2018;378(5):417-427. doi:10.1056/NEJMoa1707855
Packer DL, Mark DB, Robb RA, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation. JAMA. 2019;321(13):1261. doi:10.1001/jama.2019.0693
Zhou AL, Etchill EW, Giuliano KA, et al. Bridge to transplantation from mechanical circulatory support: a narrative review. J Thorac Dis. 2021;13(12):6911-6923. doi:10.21037/jtd-21-832
Cikes M, Jakus N, Claggett B, et al. Cardiac implantable electronic devices with a defibrillator component and all‐cause mortality in left ventricular assist device carriers: results from the PCHF‐VAD registry. Eur J Heart Fail. 2019;21(9):1129-1141. doi:10.1002/ejhf.1568
Chaudhry S, DeVore AD, Vidula H, et al. Left Ventricular Assist Devices: A Primer For the General Cardiologist. J Am Heart Assoc. 2022;11(24). doi:10.1161/JAHA.122.027251
Radreau M, Lorenzo-Villalba N, Talha S, et al. Evaluation of the French National Program on Home Return of Patients with Chronic Heart Failure (PRADO-IC): Pilot Study of 91 Patients During Its Deployment in the Bas Rhin Area. J Clin Med. 2020;9(4):1222. doi:10.3390/jcm9041222
Januzzi JL, Chen-Tournoux AA, Christenson RH, et al. N-Terminal Pro–B-Type Natriuretic Peptide in the Emergency Department. J Am Coll Cardiol. 2018;71(11):1191-1200. doi:10.1016/j.jacc.2018.01.021
Pandey A, Kitzman D, Whellan DJ, et al. Frailty Among Older Decompensated Heart Failure Patients. JACC Heart Fail. 2019;7(12):1079-1088. doi:10.1016/j.jchf.2019.10.003
McLellan J, Heneghan CJ, Perera R, et al. B-type natriuretic peptide-guided treatment for heart failure. Cochrane Database of Systematic Reviews. 2016;2016(12). doi:10.1002/14651858.CD008966.pub2
Myhre PL, Vaduganathan M, Claggett B, et al. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan. J Am Coll Cardiol. 2019;73(11):1264-1272. doi:10.1016/j.jacc.2019.01.018
Khan MS, Samman Tahhan A, Vaduganathan M, et al. Trends in prevalence of comorbidities in heart failure clinical trials. Eur J Heart Fail. 2020;22(6):1032-1042. doi:10.1002/ejhf.1818
Matsue Y, Kamiya K, Saito H, et al. Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure: the FRAGILE‐HF cohort study. Eur J Heart Fail. 2020;22(11):2112-2119. doi:10.1002/ejhf.1926
Ishak WW, Edwards G, Herrera N, et al. Depression in Heart Failure: A Systematic Review. Innov Clin Neurosci. 2020;17(4-6):27-38.
Becher PM, Schrage B, Benson L, et al. Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the S wedish H eart F ailure R egistry. Eur J Heart Fail. 2021;23(11):1844-1854. doi:10.1002/ejhf.2338
Sierpinski R, Josiak K, Suchocki T, et al. High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. Eur J Heart Fail. 2021;23(6):919-932. doi:10.1002/EJHF.2036
Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-829. doi:10.1016/S0140-6736(20)31824-9
Kalra PR, Cleland JGF, Petrie MC, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10369):2199-2209. doi:10.1016/S0140-6736(22)02083-9
Jankowska EA, Kirwan BA, Kosiborod M, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. Eur Heart J. 2021;42(31):3011. doi:10.1093/EURHEARTJ/EHAB234
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Sidhi Laksono, Syukran
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
License and Copyright Agreement
In submitting the manuscript to the journal, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal. Please also carefully read Ahmad Dahlan Medical Journal posting Your Article Policy.
- That it is not under consideration for publication elsewhere.
- That its publication has been approved by all the author(s) and by the responsible authorities - tacitly or explicitly - of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
Copyright
Authors who publish with Ahmad Dahlan Medical Journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
